Clinical trials: Parotid Gland Disorders
Measles; Mumps; Rubella, Measles-Mumps-Rubella Vaccine
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' trivalent MMR (Priorix), comparing it to Merck's MMR vaccine (M-M-R II), which is approved for use in the US in healthy children 12 to 15…
- Trial name
- NCT02184572
- Testing
- Priorix, M-M-R II, Varivax
- Where
- 95 sites in United States, Estonia and 3 more
- Volunteers
- 1,742 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Measles, Mumps
A Study of ProQuad™ in Healthy Children in Korea (V221-023)
This study will compare ProQuad™ and concomitant administration of M-M-R™ II and Varivax™ with respect to immunogenicity, safety and tolerability.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00839917
- Testing
- Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (ProQuad™), M-M-R™ II and Varivax™
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Measles-Mumps-Rubella
Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months
To evaluate the Immunogenicity and Safety of Shanghai Institute of Biological Products Co., Ltd.'s Measles, Mumps and Rubella (MMR) Vaccine Compared to a Licensed and WHO Prequalified GSK MMR Vaccine in Healthy African Children…
- Trial name
- NCT06399003
- Testing
- SIBP MMR Vaccine, GSK MMR Vaccine (PRIORIX), Yellow Fever Vaccine (Stamaril)
- Where
- Kenya
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Measles, Mumps
A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)
The study was conducted to determine if ProQuad may be used in place of the second dose of M-M-R II routinely given to children 4 to 6 years old who were previously immunized with M-M-R II and Varivax.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00985166
- Testing
- ProQuad (Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live), Comparator: M-M-R II, Comparator: Varivax
- Volunteers
- 801 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Mumps, Rubella
Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
This is a study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals live attenuated measles-mumps-rubella-varicella vaccine given to healthy children in their second year of life.
- Conditions
- Mumps, Rubella, Measles, Varicella
- Trial name
- NCT00126997
- Testing
- Measles, Mumps, Rubella and Chickenpox (live vaccine)
- Where
- 54 sites in Finland, Germany and 2 more
- Volunteers
- 1,439 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Measles, Mumps
Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine
This study will evaluate the immunogenicity and safety of Beijing Tiantan's MMR vaccine in subjects 18 months of age and older. The MMR vaccine may be administered as a second dose to 4-6 year-old persons with one dose…
- Conditions
- Measles, Mumps, Rubella, Adverse Event Following Immunisation
- Trial name
- NCT03160820
- Testing
- Measles, mumps and rubella Combined Vaccine, Live
- Where
- 4 sites in China
- Volunteers
- 873 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention, China
Diphtheria, Tetanus
Seroimmunity 2007 and Sub Study of the Swedish Population Regarding Vaccine Preventable Disease
This is a randomized cross-sectional study of the Swedish population. Blood samples will be collected from a subpopulation in order to estimate the age specific sero-prevalence of the Swedish population for diseases included in…
- Conditions
- Diphtheria, Tetanus, Pertussis, Polio
- Trial name
- Sero 2007 (NCT00932269)
- Where
- Sweden
- Volunteers
- 5,400 people, healthy volunteers welcome
- Sponsor
- Swedish Institute for Infectious Disease Control
Varicella, Measles
Safety Study of a Refrigerator-stable Formulation of VARIVAX®
Primary objective: To describe the safety profile of a refrigerator-stable formulation of VARIVAX® as a first single dose injection in 12 to 15 month-old infants in the 42-day follow-up period post-vaccination.
- Conditions
- Varicella, Measles, Mumps, Rubella
- Trial name
- NCT00432731
- Testing
- VARIVAX®, M-M-RTM II
- Where
- 25 sites in France, Italy
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Measles, Mumps
ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED)
This study will compare Measles, Mumps, Rubella, and Varicella Vaccine (V221) and concomitant administration of Varivax and M-M-R II vaccines in healthy children.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00975507
- Testing
- Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live, Comparator: Varivax, Comparator: M-M-R II
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Measles, Mumps
Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines
This study will assess the safety and immunogenicity of ProQuad when administered concomitantly and nonconcomitantly with Tripedia and Comvax.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00984295
- Testing
- Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live, Comparator: Tripedia, Comparator: Comvax
- Volunteers
- 1,913 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy, Salivary Gland Disease
Salivary Evaluation in Healthy Volunteers
Saliva is critical in maintaining oral health and comfort. Our laboratory has investigated several disorders of salivary glands.
- Trial name
- NCT00001390
- Where
- United States
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Measles, Mumps
Responses of Premature Infants to Measles-Mumps-Rubella (MMR) and Varicella Vaccines
The purpose of this study is to see if the MMR and chickenpox vaccines work as well in premature infants as in children that were carried to full term.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00138255
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Measles, Mumps
A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)
The purpose of this study is to determine the mumps virus strength at the end of shelf-life (expiration date) of an approved vaccine.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00092391
- Testing
- Comparator: M-M-R(TM) II, measles, mumps, and rubella virus vaccine live, Comparator: VARIVAX(TM) Varicella Virus Vaccine Live (Oka-Merck)
- Volunteers
- 1,997 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Varicella, Rubella
Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™
As measles-mumps-rubella (MMR) vaccination is established as routine childhood practice in most industrialised countries and varicella vaccination is now being introduced in many countries during the second year of life, a…
- Conditions
- Varicella, Rubella, Measles, Mumps
- Trial name
- NCT00353288
- Testing
- MeMuRu-OKA (study vacc), MMR, Varicella vacc (control)
- Where
- 39 sites in France, Germany and 1 more
- Volunteers
- 446 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Mumps
Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants
The purpose of this study is to evaluate the immunogenicity and safety of a live attenuated mumps vaccine in healthy infants between 8 - 18 months old with a commercialized live attenuated mumps vaccine as the control vaccine.
- Trial name
- NCT02692599
- Testing
- investigational live attenuated mumps vaccine, control live attenuated mumps vaccine
- Where
- China
- Volunteers
- 1,150 people, healthy volunteers welcome
- Sponsor
- Sinovac (Dalian) Vaccine Technology Co., Ltd.
Measles, Mumps
Safety Study of ProQuad® rHA in Infants (V221-037)
Primary objective: To describe the safety profile of a second dose of ProQuad® manufactured with recombinant human albumin (rHA) when administered to children in their second year of life.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00560755
- Testing
- ProQuad®
- Volunteers
- 3,388 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
SARS-CoV-2 Infection, Varicella
Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated Vaccines
Eligible participants were randomly assigned (1:1:1), using block randomization stratified, to either 3 groups. Group 1 will be immunized inactivated SARS-CoV-2 vaccine and varicella vaccine in day 0 followed by…
- Conditions
- SARS-CoV-2 Infection, Varicella, Measles, Mumps
- Trial name
- NCT05952505
- Testing
- Inactivated SARS-CoV-2 vaccine coadministered with vricella vaccine, Inactivated SARS-CoV-2 vaccine coadministered with MMR, Inactivated SARS-CoV-2 vaccine administered alone
- Where
- China
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Shanghai Municipal Center for Disease Control and Prevention
Mumps, Rubella
Serological Study in Children 12 to 23 Months Vaccinated With MMR (Measles, Mumps and Rubella)
On a previous study conducted in Brazil. The MMR vaccine from 2 different producers had a mumps seroconversion much lower (71%) than the expected 95%, according to the package insert.
- Conditions
- Mumps, Rubella, Measles
- Trial name
- NCT01874457
- Testing
- MMR (Mumps, Measles and Rubella)
- Where
- Brazil
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Measles, Mumps
Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED)
This study will compare three consistency lots of ProQuad to each other as well as to M-M-R II and Varivax, administered concomitantly at different injection sites, with respect to immunogenicity, safety, and tolerability.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00985153
- Testing
- Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live, Comparator: Varivax, Comparator: M-M-R II
- Volunteers
- 3,927 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Measles, Varicella
Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds
This study is undertaken to generate clinical data on GSK Biologicals' combined measles-mumps-rubella-varicella vaccine manufactured with measles and rubella obtained from newly established working seed viruses which are one…
- Conditions
- Measles, Varicella, Mumps, Rubella
- Trial name
- NCT00892775
- Testing
- Priorix-Tetra (combined measles-mumps-rubella-varicella vaccine), GSK Biologicals' 208136, new formulation
- Where
- 6 sites in Singapore, Taiwan
- Volunteers
- 501 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline